New hope for tough breast cancer cases: experimental combo targets tumors that outsmarted standard therapy
NCT ID NCT07182721
Summary
This study is testing whether a new two-drug combination (SKB264 plus inetetamab) can help control advanced HER2-positive breast cancer that has continued to grow despite previous treatment with the standard drug T-DXd. The trial will enroll 48 adults whose cancer has spread and cannot be surgically removed. Researchers will measure how many patients' tumors shrink and monitor side effects to see if this approach is safe and effective for this difficult-to-treat situation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.